Organon, a global healthcare company with a focus on women’s health, entered into an agreement with Eli Lilly and Company to become the sole distributor and promoter for the migraine medicines Emgality (galcanezumab) and RAYVOW (lasmiditan) in Europe.

Emgality, a humanized monoclonal antibody calcitonin gene-related peptide (CGRP) antagonist, is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month. RAYVOW is a first-in-class serotonin 5-HT1F receptor agonist approved for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Under the terms of the agreement, Organon will become the sole distributor and promoter of Emgality and RAYVOW in Europe. Lilly will remain the marketing authorization holder and will manufacture the products for sale.

Lilly will be paid $50 million upfront and sales-based milestone payments. The transaction is expected to close in Q1 2024.

“This commercialization agreement aligns seamlessly with Organon’s suite of central nervous system treatments in our established brands portfolio and, most importantly, it further bolsters our offerings to women, who are disproportionately impacted by migraine,” said Kevin Ali, Organon CEO. “Our strong commercial expertise and proven track record in this therapeutic area will help enable us to bring these important treatments to more patients across Europe who need them.”